PALI

Palisade BioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.35

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Most likely

Base case

40%

Probability

Target price

$1.35

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.65

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-02

AI commentary

The September 22–28 company announcements improve milestone visibility versus the August filing and supersede the prior baseline’s still-pending Crohn’s IND catalyst, but do not resolve efficacy risk. Available public peers offer clinical context, not reliable valuation comparability; the thesis remains tentative. The packet supplies no measured news, social, options, short-interest, employee, or analyst-revision series; zero-valued fields mean unavailable, not neutral. The $1.43 anchor is below the prior baseline’s $1.45, and the negative deterministic prior supports cautious monitoring.

RankAlpha Sentiment Codex - 2026-10-02

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-10-20eventUEG Week PALI-2108 presentationsMedium impact

Palisade plans four presentations on October 18–20 covering previously observed Phase 1b clinical and translational findings. New detail could affect confidence, but these presentations are not a Phase 2 efficacy readout. [#PR-2026-09-28] Source: https://www.globenewswire.com/news-release/2026/09/28/3369880/0/en/palisade-bio-to-present-clinical-and-translational-data-for-pali-2108-in-ulcerative-colitis-and-crohn-s-disease-at-ueg-week-2026.html

2026-12-31catalystASCENTRA-UC first-patient dosingHigh impact

After U.S. IND and Canadian clinical-trial clearance, Palisade says it remains on track to begin dosing in its approximately 204-patient Phase 2 ulcerative-colitis trial in the second half of 2026. Dosing would confirm execution, not efficacy; delay would weaken confidence. [#8-K-2026-08-10] [#PR-2026-09-23] Sources: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-20260810.htm and https://www.globenewswire.com/news-release/2026/09/23/3367474/0/en/palisade-bio-expands-global-phase-2b-ascentra-uc-program-with-health-canada-cta-clearance.html

2027-03-31eventASCENTRA-CD first-patient dosingHigh impact

The company announced FDA clearance of the Crohn’s disease IND on September 22, superseding August guidance that submission was still pending. It targets first dosing in its approximately 60-patient, single-arm Phase 2 study in Q1 2027. [#SEC-8K-2026-08-10] [#PR-2026-09-22] Sources: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000017/pali-ex99_1.htm and https://www.globenewswire.com/de/news-release/2026/09/22/3366355/0/en/palisade-bio-receives-fda-clearance-of-ind-for-pali-2108-in-crohn-s-disease-expanding-phase-2-development-across-ibd.html

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-02 • Updated nightlySource: Internal modelMethodology